08:34 AM EDT, 08/05/2025 (MT Newswires) -- Harmony Biosciences ( HRMY ) reported Q2 adjusted earnings Tuesday of $0.92 per diluted share, up from $0.43 a year earlier.

Five analysts polled by FactSet expected $0.97.

Revenue for the quarter ended June 30 was $200.5 million, up from $172.8 million a year ago.

Analysts surveyed by FactSet expected $204.2 million.

The pharmaceutical company said it continues to expect 2025 revenue of $820 million to $860 million. Analysts polled by FactSet expect $844.0 million.

The company's shares were down more than 8% in recent premarket activity.